Physician profile
Hari Reddy
NPI 1235199621
$30,802.43
in general payments reported to CMS, 2019-2025
27 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $366 · 2021: $1,004 · 2022: $1,496 · 2023: $1,232 · 2024: $14K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $6,406 · Consulting Fee: $1,719 · Travel and Lodging: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,200.00 |
| Food and Beverage | $6,406.19 |
| Consulting Fee | $1,719.00 |
| Travel and Lodging | $1,218.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $20,400.61 | 2019-2025 | Xolair |
| Genzyme Corporation | $3,491.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,384.26 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,765.21 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $438.81 | 2019-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $365.52 | 2019-2025 | |
| Abbvie INC. | $351.24 | 2022-2024 | |
| Ars Pharmaceuticals Operations, INC. | $207.59 | 2025 | Neffy |
| Grifols USA, LLC | $155.81 | 2024 | Xembify |
| Amgen INC. | $145.86 | 2022-2025 | Tezspire |
| Optinose US, INC. | $141.29 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.37 | 2024-2025 | Cuvitru, Takhzyro, Eohilia |
| Blueprint Medicines Corporation | $121.86 | 2025 | Ayvakit |
| Pfizer INC. | $109.06 | 2022-2023 | |
| Csl Behring | $105.61 | 2024 | Haegarda |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $86.71 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $77.02 | 2021-2022 | |
| Kaleo, INC. | $62.22 | 2019-2023 | Auvi-Q |
| Lilly USA, LLC | $62.20 | 2020-2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $40.56 | 2023 | Ryaltris |
| Organon LLC | $38.60 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $32.17 | 2020 | |
| Shire North American Group INC | $22.60 | 2019 | |
| Incyte Corporation | $20.43 | 2022 | |
| Novo Nordisk INC | $16.90 | 2023 | Wegovy |
| Galderma Laboratories, L.P. | $15.86 | 2025 | Nemluvio |
| Exact Sciences Corporation | $13.98 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hari Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.